126 related articles for article (PubMed ID: 21094231)
1. Dermal targeting of tacrolimus using colloidal carrier systems.
Goebel AS; Neubert RH; Wohlrab J
Int J Pharm; 2011 Feb; 404(1-2):159-68. PubMed ID: 21094231
[TBL] [Abstract][Full Text] [Related]
2. Dermal targeting using colloidal carrier systems with linoleic acid.
Goebel AS; Knie U; Abels C; Wohlrab J; Neubert RH
Eur J Pharm Biopharm; 2010 Jun; 75(2):162-72. PubMed ID: 20170728
[TBL] [Abstract][Full Text] [Related]
3. Development and evaluation of colloidal modified nanolipid carrier: application to topical delivery of tacrolimus.
Pople PV; Singh KK
Eur J Pharm Biopharm; 2011 Sep; 79(1):82-94. PubMed ID: 21447390
[TBL] [Abstract][Full Text] [Related]
4. Dermal peptide delivery using enhancer moleculs and colloidal carrier systems. Part II: Tetrapeptide PKEK.
Neubert RHH; Sommer E; Schölzel M; Tuchscherer B; Mrestani Y; Wohlrab J
Eur J Pharm Biopharm; 2018 Mar; 124():28-33. PubMed ID: 29247690
[TBL] [Abstract][Full Text] [Related]
5. Dermal delivery of desmopressin acetate using colloidal carrier systems.
Getie M; Wohlrab J; Neubert RH
J Pharm Pharmacol; 2005 Apr; 57(4):423-7. PubMed ID: 15831201
[TBL] [Abstract][Full Text] [Related]
6. Study of tolnaftate release from fatty acids containing ointment and penetration into human skin ex vivo.
Kezutyte T; Drevinskas T; Maruska A; Rimdeika R; Briedis V
Acta Pol Pharm; 2011; 68(6):965-73. PubMed ID: 22125963
[TBL] [Abstract][Full Text] [Related]
7. Development and evaluation of colloidal modified nanolipid carrier: application to topical delivery of tacrolimus, Part II--in vivo assessment, drug targeting, efficacy, and safety in treatment for atopic dermatitis.
Pople PV; Singh KK
Eur J Pharm Biopharm; 2013 May; 84(1):72-83. PubMed ID: 23246619
[TBL] [Abstract][Full Text] [Related]
8. In vitro penetration properties of solid lipid nanoparticles in intact and barrier-impaired skin.
Jensen LB; Petersson K; Nielsen HM
Eur J Pharm Biopharm; 2011 Sep; 79(1):68-75. PubMed ID: 21664463
[TBL] [Abstract][Full Text] [Related]
9. Vehicles based on a sugar surfactant: Colloidal structure and its impact on in vitro/in vivo hydrocortisone permeation.
Savić SD; Savić MM; Vesić SA; Vuleta GM; Müller-Goymann CC
Int J Pharm; 2006 Aug; 320(1-2):86-95. PubMed ID: 16730932
[TBL] [Abstract][Full Text] [Related]
10. Effect of the solid-dispersion method on the solubility and crystalline property of tacrolimus.
Joe JH; Lee WM; Park YJ; Joe KH; Oh DH; Seo YG; Woo JS; Yong CS; Choi HG
Int J Pharm; 2010 Aug; 395(1-2):161-6. PubMed ID: 20580799
[TBL] [Abstract][Full Text] [Related]
11. An alkylpolyglucoside surfactant as a prospective pharmaceutical excipient for topical formulations: the influence of oil polarity on the colloidal structure and hydrocortisone in vitro/in vivo permeation.
Savić S; Savić M; Tamburić S; Vuleta G; Vesić S; Müller-Goymann CC
Eur J Pharm Sci; 2007 Apr; 30(5):441-50. PubMed ID: 17331708
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus-loaded lecithin-based nanostructured lipid carrier and nanoemulsion with propylene glycol monocaprylate as a liquid lipid: Formulation characterization and assessment of dermal delivery compared to referent ointment.
Savić V; Ilić T; Nikolić I; Marković B; Čalija B; Cekić N; Savić S
Int J Pharm; 2019 Oct; 569():118624. PubMed ID: 31419461
[TBL] [Abstract][Full Text] [Related]
13. Compatibility of desoximetasone and tacrolimus.
Levitt J; Feldman T; Riss I; Leung OT
J Drugs Dermatol; 2003 Dec; 2(6):640-2. PubMed ID: 14711143
[TBL] [Abstract][Full Text] [Related]
14. Preparation and in vitro evaluation of a pluronic lecithin organogel containing ricinoleic acid for transdermal delivery.
Boddu SH; Bonam SP; Wei Y; Alexander K
Int J Pharm Compd; 2014; 18(3):256-61. PubMed ID: 25306775
[TBL] [Abstract][Full Text] [Related]
15. Targeting tacrolimus to deeper layers of skin with improved safety for treatment of atopic dermatitis.
Pople PV; Singh KK
Int J Pharm; 2010 Oct; 398(1-2):165-78. PubMed ID: 20637847
[TBL] [Abstract][Full Text] [Related]
16. Bicellar systems for in vitro percutaneous absorption of diclofenac.
Rubio L; Alonso C; Rodríguez G; Barbosa-Barros L; Coderch L; De la Maza A; Parra JL; López O
Int J Pharm; 2010 Feb; 386(1-2):108-13. PubMed ID: 19922782
[TBL] [Abstract][Full Text] [Related]
17. Dermal peptide delivery using colloidal carrier systems.
Goebel A; Neubert RH
Skin Pharmacol Physiol; 2008; 21(1):3-9. PubMed ID: 17912018
[TBL] [Abstract][Full Text] [Related]
18. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes.
Dubey V; Mishra D; Dutta T; Nahar M; Saraf DK; Jain NK
J Control Release; 2007 Nov; 123(2):148-54. PubMed ID: 17884226
[TBL] [Abstract][Full Text] [Related]
19. Niosomes as carriers for tretinoin. III. A study into the in vitro cutaneous delivery of vesicle-incorporated tretinoin.
Manconi M; Sinico C; Valenti D; Lai F; Fadda AM
Int J Pharm; 2006 Mar; 311(1-2):11-9. PubMed ID: 16439071
[TBL] [Abstract][Full Text] [Related]
20. Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis.
Lapteva M; Mondon K; Möller M; Gurny R; Kalia YN
Mol Pharm; 2014 Sep; 11(9):2989-3001. PubMed ID: 25057896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
